Maia Biotechnology Stock Performance
| MAIA Stock | USD 1.76 0.01 0.57% |
The firm secures a Beta (Market Risk) of 0.48, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, MAIA Biotechnology's returns are expected to increase less than the market. However, during the bear market, the loss of holding MAIA Biotechnology is expected to be smaller as well. At this point, MAIA Biotechnology has a negative expected return of -0.0885%. Please make sure to verify MAIA Biotechnology's potential upside, daily balance of power, and the relationship between the maximum drawdown and kurtosis , to decide if MAIA Biotechnology performance from the past will be repeated in the future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days MAIA Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong forward indicators, MAIA Biotechnology is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
1 | Acquisition by Theagene Jean-manasse of 10225 shares of MAIA Biotechnology at 1.98 subject to Rule 16b-3 | 12/31/2024 |
2 | MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer | 02/04/2025 |
3 | Acquisition by Jeffrey Himmelreich of 10000 shares of MAIA Biotechnology at 1.81 subject to Rule 16b-3 | 02/10/2025 |
4 | October 7thmade me realize being trans is a luxury belief so Im detransitioning | 02/20/2025 |
5 | Insider Buying Ramiro Guerrero Acquires 73,333 Shares of MAIA Biotechnology Inc | 02/25/2025 |
6 | MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell... | 02/27/2025 |
7 | Acquisition by Smith Stan of 25000 shares of MAIA Biotechnology at 1.85 subject to Rule 16b-3 | 03/03/2025 |
8 | MAIA Biotechnology Expected to Announce Earnings on Thursday - Defense World | 03/13/2025 |
9 | Acquisition by Jeffrey Himmelreich of 10000 shares of MAIA Biotechnology at 2.94 subject to Rule 16b-3 | 03/17/2025 |
10 | MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug | 03/20/2025 |
| Begin Period Cash Flow | 11 M | |
| Free Cash Flow | -13.1 M |
MAIA |
MAIA Biotechnology Relative Risk vs. Return Landscape
If you would invest 197.00 in MAIA Biotechnology on December 22, 2024 and sell it today you would lose (21.00) from holding MAIA Biotechnology or give up 10.66% of portfolio value over 90 days. MAIA Biotechnology is currently does not generate positive expected returns and assumes 4.4451% risk (volatility on return distribution) over the 90 days horizon. In different words, 39% of stocks are less volatile than MAIA, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
MAIA Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MAIA Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as MAIA Biotechnology, and traders can use it to determine the average amount a MAIA Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0199
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MAIA |
Estimated Market Risk
| 4.45 actual daily | 39 61% of assets are more volatile |
Expected Return
| -0.09 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average MAIA Biotechnology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MAIA Biotechnology by adding MAIA Biotechnology to a well-diversified portfolio.
MAIA Biotechnology Fundamentals Growth
MAIA Stock prices reflect investors' perceptions of the future prospects and financial health of MAIA Biotechnology, and MAIA Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MAIA Stock performance.
| Return On Equity | -11.88 | ||||
| Return On Asset | -1.41 | ||||
| Current Valuation | 42.21 M | ||||
| Shares Outstanding | 28.92 M | ||||
| Price To Book | 31.45 X | ||||
| EBITDA | (20.18 M) | ||||
| Net Income | (19.77 M) | ||||
| Cash And Equivalents | 8.15 M | ||||
| Cash Per Share | 0.75 X | ||||
| Total Debt | 7.09 M | ||||
| Current Ratio | 2.78 X | ||||
| Book Value Per Share | 0.07 X | ||||
| Cash Flow From Operations | (13.07 M) | ||||
| Earnings Per Share | (1.34) X | ||||
| Market Capitalization | 50.9 M | ||||
| Total Asset | 7.57 M | ||||
| Retained Earnings | (63.98 M) | ||||
| Working Capital | 2.63 M | ||||
About MAIA Biotechnology Performance
By analyzing MAIA Biotechnology's fundamental ratios, stakeholders can gain valuable insights into MAIA Biotechnology's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if MAIA Biotechnology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if MAIA Biotechnology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.29) | (2.40) | |
| Return On Capital Employed | (2.68) | (2.81) | |
| Return On Assets | (2.29) | (2.40) | |
| Return On Equity | (6.40) | (6.08) |
Things to note about MAIA Biotechnology performance evaluation
Checking the ongoing alerts about MAIA Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for MAIA Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MAIA Biotechnology generated a negative expected return over the last 90 days | |
| MAIA Biotechnology may become a speculative penny stock | |
| MAIA Biotechnology has high historical volatility and very poor performance | |
| MAIA Biotechnology has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (19.77 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| MAIA Biotechnology currently holds about 8.15 M in cash with (13.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.75. | |
| MAIA Biotechnology has a poor financial position based on the latest SEC disclosures | |
| Roughly 26.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug |
- Analyzing MAIA Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MAIA Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining MAIA Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MAIA Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of MAIA Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MAIA Biotechnology's stock. These opinions can provide insight into MAIA Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for MAIA Stock analysis
When running MAIA Biotechnology's price analysis, check to measure MAIA Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MAIA Biotechnology is operating at the current time. Most of MAIA Biotechnology's value examination focuses on studying past and present price action to predict the probability of MAIA Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MAIA Biotechnology's price. Additionally, you may evaluate how the addition of MAIA Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |